DACOMITINIB

Search structure
Trade Names:
Synonyms:
Status: Approved (2018)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: L01EB07
UNII: 2XJX250C20

Structure
InChI Key LVXJQMNHJWSHET-AATRIKPKSA-N
Smile COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1
InChI
InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+

Physicochemical Descriptors

Property Name Value
Molecular Formula C24H25ClFN5O2
Molecular Weight 469.95
AlogP 5.16
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 7.0
Polar Surface Area 79.38
Molecular species BASE
Aromatic Rings 3.0
Heavy Atoms 33.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Epidermal growth factor receptor erbB1 inhibitor PubMed Other
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase EGFR family
- 2-42 - - -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase JakA family
- 3570 - - -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase JakB family
- 3570 - - -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Src family
- 94-94000 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Neoplasms 4 D009369 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 4 D002289 FDA
Carcinoma, Non-Small-Cell Lung 3 D002289 ClinicalTrials
Lung Neoplasms 3 D008175 ClinicalTrials
Penile Neoplasms 2 D010412 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Carcinoma 2 D002277 ClinicalTrials
Glioblastoma 2 D005909 ClinicalTrials
Head and Neck Neoplasms 2 D006258 ClinicalTrials
Brain Neoplasms 2 D001932 ClinicalTrials
Brain Neoplasms 2 D001932 ClinicalTrials
Colorectal Neoplasms 1 D015179 ClinicalTrials
Liver Diseases 1 D008107 ClinicalTrials
Neoplasm Metastasis 1 D009362 ClinicalTrials
Mouth Neoplasms 1 D009062 ClinicalTrials

Related Entries

MCS

Scaffolds

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Respiratory, thoracic and mediastinal disorders
17.11
Cardiac disorders
15.79
Gastrointestinal disorders
14.47
Hepatobiliary disorders
10.53
General disorders and administration site conditions
9.21
Infections and infestations
5.26
Psychiatric disorders
5.26
Renal and urinary disorders
5.26
Vascular disorders
5.26
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
3.95
Injury, poisoning and procedural complications
2.63
Nervous system disorders
2.63
Skin and subcutaneous tissue disorders
2.63

Cross References

Resources Reference
CAS NUMBER 1110813-31-4
ChEBI 132268
ChEMBL CHEMBL2110732
DrugBank DB11963
DrugCentral 5297
EPA CompTox DTXSID50149493
FDA SRS 2XJX250C20
Guide to Pharmacology 7422
PDB 1C9
PubChem 70693519
SureChEMBL SCHEMBL25637
ZINC ZINC000072266312
CAS NUMBER 1110813-31-4
ChEMBL CHEMBL2105719
EPA CompTox DTXSID80146359
FDA SRS 5092U85G58
Guide to Pharmacology 7422
PubChem 70693519
SureChEMBL SCHEMBL22498351
CONTENTS